Boehringer Ingelheim VTE treatment shows efficacy in trial

Boehringer Ingelheim has published new clinical research data which underlines the safety and efficacy of dabigatran etexilate, its treatment for preventing venous thromboembolism (VTE) after total hip replacement surgery.

The drug was trialled in Re-Novate II, a phase III clinical trial involving 2,055 patients that compared the performance of dabigatran etexilate with enoxaparin.

It was found that Boehringer Ingelheim’s drug was as effective as the alternative in preventing total VTE and related fatalities, while major bleeding events were comparable between both treatments.

Dr Michael Huo, of the department of orthopaedic surgery at the University of Texas Southwestern Medical Center, stated that these clinical benefits are also allied with cost-saving advantages, due to its oral administration.

He added: “As dabigatran etexilate is administered orally, it is more convenient than injectable anticoagulants such as enoxaparin for patients outside of the hospital setting.”

Earlier this week, Boehringer Ingelheim published a report to reinforce the safety profile of telmisartan, its angiotensin receptor blocker treatment for heart disease.